Late last year I was hearing some exciting things about California Stem Cell, Inc. under the leadership of Hans Keirstead. (2020 update: interestingly 3 years ago Keirstead ran for congress, but the campaign didn’t quite make it.) In fact, I thought a big move for California Stem was in the cards for 2014 and looking into …
As Predicted, Big News For California Stem Cell, Inc.: Purchased by NeoStem Read More »
A long-standing debate in the commercial stem cell arena has focused on whether stem cells grown in a lab prior to clinical use as a transplantation product are biological drugs subject to full FDA vetting. The alternative view has been that such stem cell products are not drugs, but rather are simple human cellular and …
Court in Regenerative Sciences Case: Propagated Stem Cells Are Drugs Read More »
The STAP papers on making iPS like cells using acid treatment of differentiated cells really has people talking. See embryo at right made from GFP reporter STAP cells that glow green. As I said in my review of the papers yesterday, there are still some critical things we do not know about STAP cells and I …
More thoughts from STAP acid reprogramming stem cell paper Read More »
So what’s going to happen in today’s NFC Championship game between the Seahawks and 49ers. As someone who lives in Davis, CA just about an hour from San Francisco, you might think I’d be a 49ers fan. However, I grew up in Seattle, spent many hours in the Kingdome, and I am in fact a …
One of the big stem cell-related stories of 2013 was the controversy over the Stamina Foundation in Italy and its potential use of largely untested stem cell products on patients, including mostly children. The winner of my 2013 Stem Cell Person of the Year Award was Dr. Elena Cattaneo and one reason she won was the courage …
Nature Slams Controversial Stamina Foundation: A Dangerous Situation Continues Read More »
Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made …
J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »
The World Stem Cell Summit in San Diego was a great meeting this past week. It was my 3rd straight Summit and the best of all. It’s a unique mix of science, medicine, and policy that links together key players from every corner of the field. I talked stem cells one-on-one or in small groups …
Every now and I then I try to take some time to think about the focus of this blog and the direction it is going. In the most recent case, I got the feeling that perhaps I have giving too discouraged or negative an impression on the blog lately….focusing too much on the challenges and …
Why I am very optimistic about the future of the stem cell field Read More »
This is the fourth post in a series I’m doing on an FOIA release of letters between Texas stem cell clinic Celltex and the FDA. The first three posts, which include helpful background and discussion of other FOIA material from Celltex, can be found here, here, and here. Today’s post is focused on a newly …
Celltex FDA FOIA Letter #3 Raises Key New Questions Read More »
What does homologous use mean? Navigating the arena of clinical use of a biologic such as stem cells or differentiated cells made from stem cells can be challenging. There are many important issues including what defines “minimal manipulation” of biologics such as cells. One particular issue that is critically important and has drawn less attention …
Time to bone up on homologous use in the stem cell field Read More »